Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    33.629,21
    -107,19 (-0,32%)
     

  • Dow Jones

    38.677,71
    +452,05 (+1,18%)
     

  • Nasdaq

    16.167,64
    +326,68 (+2,06%)
     

  • Nikkei 225

    38.236,07
    -37,98 (-0,10%)
     

  • Petrolio

    78,05
    -0,90 (-1,14%)
     

  • Bitcoin EUR

    57.264,29
    +2.294,74 (+4,17%)
     

  • CMC Crypto 200

    1.337,60
    +60,63 (+4,74%)
     

  • Oro

    2.305,30
    -4,30 (-0,19%)
     

  • EUR/USD

    1,0772
    +0,0045 (+0,42%)
     

  • S&P 500

    5.130,41
    +66,21 (+1,31%)
     

  • HANG SENG

    18.475,92
    +268,79 (+1,48%)
     

  • Euro Stoxx 50

    4.921,48
    +30,87 (+0,63%)
     

  • EUR/GBP

    0,8579
    +0,0024 (+0,29%)
     

  • EUR/CHF

    0,9745
    -0,0014 (-0,14%)
     

  • EUR/CAD

    1,4732
    +0,0070 (+0,48%)
     

Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023

Crinetics Pharmaceuticals, Inc.
·1 minuto per la lettura
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc.

SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference, which is being held in New York City on September 26-28, 2023.

Details of the fireside chat are as follows:

Date: Tuesday, September 26, 2023
Time: 1:00 p.m. Eastern Time

The live and archived webcast will be accessible on the Events & Presentations page in the Investors section on the Crinetics’ website at www.crinetics.com/events.

If you are interested in arranging a 1×1 meeting with management, please contact your Cantor representative.

ANNUNCIO PUBBLICITARIO

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894 a first-in-class, investigational, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of Cushing’s disease and congenital adrenal hyperplasia. All of the Company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, hyperinsulinism, diabetes and obesity.

Contacts:
Chas Schultz
VP, IR & Corporate Communications
cschultz@crinetics.com
(858) 450-6464

Investors:
Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com
(212) 915-2577

Media:
Jenn Gordon
Spectrum Science
jgordon@spectrumscience.com
(202) 957-7795